Tongfang Kontafarma Holdings Limited (1312.HK)

HKD 0.03

(3.57%)

Market Cap (In HKD)

161.78 Million

Revenue (In HKD)

809.1 Million

Net Income (In HKD)

-28.84 Million

Avg. Volume

1.08 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.026-0.048
PE
-2.9
EPS
-0.01
Beta Value
0.031
ISIN
KYG8918D1088
CUSIP
G8918D108
CIK
-
Shares
5578712000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Feifei Wang
Employee Count
-
Website
https://www.tfkf.com.hk
Ipo Date
2012-01-18
Details
Tongfang Kontafarma Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs and laboratory related products in Mainland China, Singapore, Taiwan, and the United States. The company operates in Pharmaceutical Business and Fitness Business segments. It also offers chemical drugs and prescribed traditional Chinese medicines; operates fitness centers; operates in the franchise business; and provides consultation services for fitness and health activities. The company trades in laboratory related products; researches and develops medical products; and offers corporate advisory services. As of December 31, 2021, it operated 12 fitness centers and 2 yoga center in Taiwan; and 10 fitness centers in Singapore. The company was formerly known as Allied Cement Holdings Limited and changed its name to Tongfang Kontafarma Holdings Limited in August 2016. The company was founded in 1993 and is headquartered in Wan Chai, Hong Kong. Tongfang Kontafarma Holdings Limited is a subsidiary of China Health Management Investment Limited.